S. Wilk

3.2k total citations · 2 hit papers
38 papers, 2.8k citations indexed

About

S. Wilk is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, S. Wilk has authored 38 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Cellular and Molecular Neuroscience. Recurrent topics in S. Wilk's work include Peptidase Inhibition and Analysis (10 papers), Ubiquitin and proteasome pathways (7 papers) and Neuropeptides and Animal Physiology (5 papers). S. Wilk is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Ubiquitin and proteasome pathways (7 papers) and Neuropeptides and Animal Physiology (5 papers). S. Wilk collaborates with scholars based in United States, Germany and Mexico. S. Wilk's co-authors include E. Britta-Mareen Traenckner, Patrick A. Baeuerle, Heike L. Pahl, Kerstin Schmidt, Timothy P. Henkel, Louis J. Ignarro, Marian Orłowski, Eric Watson, Haruko Mizoguchi and Cezary Wójcik and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The EMBO Journal.

In The Last Decade

S. Wilk

38 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli.

1995 933 citations E. Britta-Mareen Traenckner, Heike L. Pahl et al. The EMBO Journal profile →
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.

1994 642 citations E. Britta-Mareen Traenckner, S. Wilk et al. The EMBO Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Wilk United States	21	1.4k	1.1k	889	514	286	38	2.8k
Gary G. Meadows United States	30	1.2k 0.8×	367 0.3×	669 0.8×	337 0.7×	185 0.6×	113	2.7k
Jeffrey T. Laydon United States	10	2.1k 1.5×	551 0.5×	812 0.9×	827 1.6×	149 0.5×	13	3.5k
Ivo R. Siemens United States	8	2.0k 1.4×	473 0.4×	702 0.8×	699 1.4×	183 0.6×	11	3.1k
Ho Sung Kang South Korea	30	1.9k 1.3×	609 0.6×	351 0.4×	555 1.1×	210 0.7×	64	2.9k
Raymond F. Brown United States	9	2.3k 1.6×	300 0.3×	612 0.7×	519 1.0×	284 1.0×	12	3.6k
Stefan Grimm United Kingdom	28	3.2k 2.2×	1.0k 1.0×	929 1.0×	470 0.9×	225 0.8×	51	4.2k
Florian Überall Austria	30	1.6k 1.1×	372 0.4×	494 0.6×	512 1.0×	153 0.5×	64	2.7k
Gary A. Clawson United States	32	1.8k 1.2×	399 0.4×	313 0.4×	590 1.1×	149 0.5×	116	3.3k
Makoto Morimoto Japan	22	3.3k 2.3×	421 0.4×	540 0.6×	664 1.3×	522 1.8×	71	5.1k
H. Grunicke Austria	34	2.3k 1.6×	325 0.3×	297 0.3×	829 1.6×	196 0.7×	123	3.3k

Countries citing papers authored by S. Wilk

Since Specialization

Citations

This map shows the geographic impact of S. Wilk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Wilk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Wilk more than expected).

Fields of papers citing papers by S. Wilk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Wilk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Wilk. The network helps show where S. Wilk may publish in the future.

Co-authorship network of co-authors of S. Wilk

This figure shows the co-authorship network connecting the top 25 collaborators of S. Wilk. A scholar is included among the top collaborators of S. Wilk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Wilk. S. Wilk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilk, S., Kihak Lee, Virgilia Macias, et al.. (2025). Multiplex imaging reveals novel patterns of MRTFA/B activation in the breast cancer microenvironment. Journal of Translational Medicine. 23(1). 599–599. 1 indexed citations

Stokłosa, Tomasz, Cezary Wójcik, Paweł Włodarski, et al.. (2004). Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. APOPTOSIS. 9(2). 193–204. 4 indexed citations

Yamanaka, Chutaro, Eric Vandersmissen, A. Gérard, et al.. (1999). Early Prepubertal Ontogeny of Pulsatile Gonadotropin-Releasing Hormone (GnRH) Secretion: I. Inhibitory Autofeedback Control through Prolyl Endopeptidase Degradation of GnRH1. Endocrinology. 140(10). 4609–4615. 50 indexed citations

Wójcik, Cezary, Tomasz Stokłosa, Adam Giermasz, et al.. (1997). Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. APOPTOSIS. 2(5). 455–462. 17 indexed citations

Jiang, Jian‐Dong, et al.. (1997). Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Research in Virology. 148(4). 255–266. 11 indexed citations

Traenckner, E. Britta-Mareen, Heike L. Pahl, Timothy P. Henkel, et al.. (1995). Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli.. The EMBO Journal. 14(12). 2876–2883. 933 indexed citations breakdown →

Figueiredo‐Pereira, Maria E., et al.. (1995). A Novel Chymotrypsin like Component of the Multicatalytic Proteinase Complex Optimally Active at Acidic pH. Archives of Biochemistry and Biophysics. 317(1). 69–78. 30 indexed citations

Griscavage, J.M., S. Wilk, & L J Ignarro. (1995). Serine and Cysteine Proteinase Inhibitors Prevent Nitric Oxide Production by Activated Macrophages by Interfering with Transcription of the Inducible NO Synthase Gene. Biochemical and Biophysical Research Communications. 215(2). 721–729. 59 indexed citations

Traenckner, E. Britta-Mareen, S. Wilk, & Patrick A. Baeuerle. (1994). A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.. The EMBO Journal. 13(22). 5433–5441. 642 indexed citations breakdown →

10.

Suen, C S & S. Wilk. (1990). Biphasic down regulation of pyroglutamyl peptidase ii a trh degrading enzyme by protein kinase c. The FASEB Journal. 4(3). 734. 1 indexed citations

11.

Wilk, S., et al.. (1990). Inhibition of angiotensin III formation by thiol derivatives of acidic amino acids. Neuropeptides. 16(3). 163–168. 26 indexed citations

12.

Cruz, Carlos, et al.. (1990). Evaluation of the role of prolyl endopeptidase and pyroglutamyl peptidase I in the metabolism of LHRH and TRH in brain. Neuropeptides. 17(2). 55–62. 29 indexed citations

13.

Charli, Jean‐Louis, et al.. (1989). Pyroglutamyl peptidase II inhibition specifically increases recovery of TRH released from rat brain slices. Neuropeptides. 14(3). 191–196. 35 indexed citations

14.

Orłowski, Marian, Haruko Mizoguchi, & S. Wilk. (1980). N-acyl-gamma-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs.. Journal of Pharmacology and Experimental Therapeutics. 212(1). 167–172. 25 indexed citations

15.

Wilk, S., Eric Watson, & Michael Stanley. (1975). Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine.. Journal of Pharmacology and Experimental Therapeutics. 195(2). 265–270. 69 indexed citations

16.

Angrist, Burton, Baron Shopsin, Samuel Gershon, & S. Wilk. (1972). Metabolites of monoamines in urine and cerebrospinal fluid, after large dose amphetamine administration. Psychopharmacology. 26(1). 1–9. 10 indexed citations

17.

Wilk, S., et al.. (1972). On the measurement of 5‐hydroxyindoleacetic acid in cerebrospinal fluid¹. Journal of Neurochemistry. 19(12). 2893–2895. 9 indexed citations

18.

Wilk, S., et al.. (1971). Cerebrospinal fluid levels of 3‐methoxy4hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L‐DOPA¹. Journal of Neurochemistry. 18(9). 1771–1773. 18 indexed citations

19.

Wilk, S., et al.. (1967). Gas Chromatographic Determination of Dopamine at the Nanogram Level. Journal of Chromatographic Science. 5(6). 307–310. 35 indexed citations

20.

Wilk, S., et al.. (1966). Electron Capture Properties of Halogenated Amine Derivatives. Journal of Chromatographic Science. 4(8). 310–313. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact